大剂量异环磷酰胺联合脂质体阿霉素治疗骨肉瘤的临床研究  

Clinical Study of Large Dose Ifosfamide Combined with Liposomal Doxorubicin for Osteosarcoma

作　　者：陈丰[1] 郭智[2] 瞿嵘[3] 

机构地区：[1]湖北省武汉市中心医院,430014 [2]北京军区总医院,100700 [3]广东省惠州市中心人民医院,516001

出　　处：《实用癌症杂志》2015年第5期676-678,共3页The Practical Journal of Cancer

基　　金：广东省医学科研基金(编号:A2013772)

摘　　要：目的观察大剂量异环磷酰胺联合脂质体阿霉素治疗原发性骨肉瘤的有效性和安全性。方法武汉市中心医院2012年1月至2014年1月应用大剂量异环磷酰胺(Ifosfamide,2 g/m2,d1~5)联合脂质体阿霉素(Liposomal Doxorubicin,20 mg/m2,d1~3)共治疗8例原发性骨肉瘤,观察其临床疗效和安全性。结果全组8例患者总有效率为87.5%(7/8),2年无瘤生存率为62.5%(5/8)。全部患者均能耐受化疗,无严重并发症发生。结论大剂量异环磷酰胺联合脂质体阿霉素治疗原发性骨肉瘤疗效肯定,值得临床推广使用。Objective To observe the efficacy and safety of large dose ifosfamide combined with liposomal doxorubicin in the treatment of osteosarcoma. Methods Clinical efficacy and safety of large dose ifosfamide( 2 g / m2,d1 ~ 5) combined with liposomal doxorubicin( 20 mg / m2,d1 ~ 3) for 8 cases of osteosarcoma were observed. Results The total effective rate was87. 5%( 7 /8),2-year disease-free survival rate was 62. 5%( 5 /8). All patients tolerated the chemotherapy and no serious complications occurred. Conclusion Large dose ifosfamide combined with liposomal doxorubicin in the treatment of osteosarcoma is safe and effective,it is worthy of clinical application.

关 键 词：骨肉瘤 异环磷酰胺 脂质体阿霉素 序贯治疗 无病生存 

分 类 号：R738.1[医药卫生—肿瘤]